Today’s Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals
U.S. markets were mixed Mondays as concerns over a potential trade war overshadowed Friday’s jobs data. The Dow Jones Industrial Average declined 0.62 percent to close at 25,178.61 and the S&P 500 Index was down 0.13 percent to close at 2,783.02. The Nasdaq Composite Index jumped 0.36 percent to close at a record 7,588.32. President Trump has implemented tariffs of 25 percent on imported steel imports and 10 percent on imported aluminum. Canada and Mexico have been excluded from the tariffs."It’s a growing concern that a mistake in trade policy could be as big as a mistake in monetary policy," said Art Hogan, chief market strategist at B. Riley FBR. RDI Initiates Coverage on: Kura Oncology, Inc.
https://rdinvesting.com/news/?ticker=KURA Zynerba Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=ZYNE Kura Oncology’s stock moved 1.53% higher Monday, to close the day at $23.25. The stock recorded a trading volume of 252,781 shares, which was below its three months average volume of 341,593 shares. In the last year, Kura Oncology’s shares have traded in a range of 5.90 – 24.02. The share price has gained 294.07% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $20.67 is greater than its 200-day moving average of $15.52. Shares of Kura Oncology have gained roughly 25.68 percent in the past month and are up 51.96 percent year-to-date. Access RDI’s Kura Oncology, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=KURA On Monday, shares of Zynerba Pharmaceuticals recorded a trading volume of 1,083,055 shares, which was above the three months average volume of 305,586 shares. The stock ended the day 15.21% higher at 10.53. The share price has gained 94.28% from its 52 week low with a 52 week trading range of 5.42 – 25.95. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $10.88 is greater than its 200-day moving average of $10.42. Shares of Zynerba Pharmaceuticals have fallen roughly 7.39 percent in the past month and are down 15.89 percent year-to-date. Access RDI’s Zynerba Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ZYNE Our Actionable Research on Kura Oncology, Inc. (NASDAQ:KURA) and Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) can be downloaded free of charge at Research Driven Investing. Research Driven Investing We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection. RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document. Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer. CONTACT For any questions, inquiries, or comments reach out to us directly at: Address: Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011 Email: [email protected] CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.